Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13276690 | 1.00 | BTK (0.40) | BTKKDM1AMAOBEZH2YAP1 | |
| SCHEMBL13276862 | 1.00 | BTK (0.40) | BTKKDM1AMAOBEZH2YAP1 | |
| SCHEMBL13276989 | 0.90 | KDM1A (0.42) | BTKKDM1AMAOBEZH2DRD2 | |
| SCHEMBL13276990 | 0.90 | KDM1A (0.42) | BTKKDM1AMAOBEZH2DRD2 | |
| SCHEMBL15732166 | 0.87 | BTK (0.40) | BTKKDM1AMAOBYAP1DRD2 | |
| SCHEMBL13280699 | 0.87 | BTK (0.40) | BTKKDM1AMAOBYAP1DRD2 | |
| SCHEMBL13467831 | 0.87 | BTK (0.48) | BTKKDM1AMAOBEZH2YAP1 | |
| SCHEMBL15711089 | 0.87 | BTK (0.48) | BTKKDM1AMAOBEZH2YAP1 | |
| SCHEMBL15710041 | 0.87 | BTK (0.40) | BTKKDM1AMAOBYAP1DRD2 | |
| SCHEMBL16398374 | 0.86 | OPRK1 (0.37) | BTKKDM1AMAOBEZH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311921-B | Aryl or heteroaryl substituted benzene compounds | EPIZYME股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | BTK 438/4885KDM1A 867/4885MAOB 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.